ClinicalTrials.gg
CompletedNCT02005549Updated Jul 14, 2014Results posted

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer

A Phase 2 interventional study of bevacizumab [Avastin] and docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in Austria. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
218th of 248
18 · median 68
Started
2006
with 16 others
Phase 2
157 of 264
11 open now
Registered
210th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 218th largest by enrollment of the 248 interventional ones that give a count, is one of 17 that started in 2006, is one of 157 in phase 2, and was the 210th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, 18-70years of age;
  • -proven invasive breast cancer;
  • no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix;
  • no distant disease/secondary cancer.

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating women;
  • pre-operative local treatment for breast cancer;
  • prior or concurrent systemic antitumor therapy;
  • cardiac disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Neoadjuvant Therapy

    Drug: bevacizumab [Avastin] · Drug: docetaxel · Drug: capecitabine [Xeloda]

Interventions

  • 15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles

  • 75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles

  • 950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pathological Complete Response (pCR)

    pCR was defined as the absence of signs for invasive tumor in the final surgical sample as judged by the local pathologist. Surgery was performed 2 to 4 weeks after the last chemotherapy cycle.

    Time frame: Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])

Secondary outcomes

  1. Percentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR)

    Percentage of participants with pCR plus the percentage of participants without pCR who achieved CR or PR as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])

  2. Percentage of Participants Undergoing Breast-Conserving Surgery

    Percentage of participants undergoing a breast-conserving procedure versus a modified radical mastectomy at final surgery, performed 2 to 4 weeks after the last chemotherapy cycle (Week 18)

    Time frame: 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])

07

Results

Posted Jun 6, 2014
Limitations and caveats
Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab+Docetaxel+Capecitabine
Started18
Completed18
Not completed0

Outcome measures

PrimaryPercentage of Participants With Pathological Complete Response (pCR)

pCR was defined as the absence of signs for invasive tumor in the final surgical sample as judged by the local pathologist. Surgery was performed 2 to 4 weeks after the last chemotherapy cycle.

Time frame:
Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response (pCR)
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants With Pathological Complete Response (pCR)22.22 (6.41 to 47.64)
SecondaryPercentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR)

Percentage of participants with pCR plus the percentage of participants without pCR who achieved CR or PR as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
Reported as:
Number · percentage of participants
Percentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR)
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR)72.22 (46.52 to 90.31)
SecondaryPercentage of Participants Undergoing Breast-Conserving Surgery

Percentage of participants undergoing a breast-conserving procedure versus a modified radical mastectomy at final surgery, performed 2 to 4 weeks after the last chemotherapy cycle (Week 18)

Time frame:
20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
Reported as:
Number · percentage of participants
Percentage of Participants Undergoing Breast-Conserving Surgery
percentage of participantsBevacizumab+Docetaxel+Capecitabine
Percentage of Participants Undergoing Breast-Conserving Surgery83 (59 to 96)

Adverse events

Collected over Baseline, every three weeks (Cycles 1 through 6), end-of-treatment, to 28 days after last dosage of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab+Docetaxel+Capecitabine—5/18 (27.8%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventBevacizumab+Docetaxel+Capecitabine
Deep vein thrombosisVascular disorders2/18
Intestinal perforationGastrointestinal disorders1/18
General physical health deteriorationGeneral disorders1/18
Impaired healingGeneral disorders1/18
Neutropenic infectionInfections and infestations1/18
Contralateral breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/18
MenorrhagiaReproductive system and breast disorders1/18
Most frequent other events
Showing 10 of 75
Most frequent other events
EventBevacizumab+Docetaxel+Capecitabine
AlopeciaSkin and subcutaneous tissue disorders17/18
Nail disorderSkin and subcutaneous tissue disorders12/18
ConstipationGastrointestinal disorders8/18
LymphopeniaBlood and lymphatic system disorders8/18
Blood lactate dehydrogenase increasedInvestigations8/18
HyperglycaemiaMetabolism and nutrition disorders8/18
FatigueGeneral disorders6/18
Pain in extremityMusculoskeletal and connective tissue disorders6/18
StomatitisGastrointestinal disorders5/18
AnaemiaBlood and lymphatic system disorders5/18

Baseline characteristics

Intent-to-treat (ITT) population. All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Bevacizumab+Docetaxel+Capecitabine
Median48 (34 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab+Docetaxel+Capecitabine
Female18
Male0
08

Study locations

1 site
  • Salzburg, 5020, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 9, 2013
Start
Feb 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 6, 2014
Last update
Jul 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02005549
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Feb 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 6, 2014
Last update
Jul 14, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion